Uridine Triacetate
Uridine triacetate is a prodrug that is cleaved in vivo to release uridine, which competitively inhibits the incorporation of fluorouracil (5-FU) metabolites into RNA and DNA, thereby rescuing normal cells from 5-FU toxicity. It is used as an antidote for 5-FU overdose or early-onset severe toxicity from 5-FU or capecitabine chemotherapy, and is also approved for hereditary orotic aciduria, a rare enzyme deficiency causing abnormal pyrimidine metabolism. Its mechanism of flooding the uridine pool reduces the relative incorporation of toxic 5-FU metabolites.
Masse moléculaire
370,3100 g/mol
LogP
-0,50
TPSA
138,00 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Counteracts the effects of a specific toxin or drug overdose through competitive antagonism, enhanced elimination, or direct chemical neutralization.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Counteracts the effects of a specific toxin or drug overdose through competitive antagonism, enhanced elimination, or direct chemical neutralization.
Structure 2D
Cite this structure
Embed this structure
SMILES
CC(=O)OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O
InChI
InChI=1S/C15H18N2O9/c1-7(18)23-6-10-12(24-8(2)19)13(25-9(3)20)14(26-10)17-5-4-11(21)16-15(17)22/h4-5,10,12-14H,6H2,1-3H3,(H,16,21,22)/t10-,12-,13-,14-/m1/s1
Molecular Formula
C15H18N2O9
HBD / HBA
1 / 9
Liaisons Rotatives
8
Atomes Lourds
26
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
Uridine triacetate is a prodrug that is cleaved in vivo to release uridine, which competitively inhibits the incorporation of fluorouracil (5-FU) metabolites into RNA and DNA, thereby rescuing normal cells from 5-FU toxicity. It is used as an antidote for 5-FU overdose or early-onset severe toxicity from 5-FU or capecitabine chemotherapy, and is also approved for hereditary orotic aciduria, a rare enzyme deficiency causing abnormal pyrimidine metabolism. Its mechanism of flooding the uridine pool reduces the relative incorporation of toxic …
Counteracts the effects of a specific toxin or drug overdose through competitive antagonism, enhanced elimination, or direct chemical neutralization.
Yes, Uridine Triacetate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2107381. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 20058. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="uridine-triacetate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/uridine-triacetate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/uridine-triacetate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/uridine-triacetate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="uridine-triacetate"></drugfyi-drug>